On February 17, 2021 Astrazeneca, The Carnot Calym Institute and Inserm Transfert for Inserm sign a framework agreement for research collaboration in lymphomas (Press release, OncoFactory, FEB 17, 2021, View Source [SID1234575981]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
In order to accelerate the search for therapeutic solutions for lymphoma patients, the three partners have decided to pool their expertise by signing a tripartite agreement. This partnership sets up the conditions for the collaboration between the pharmaceutical group AstraZeneca, research teams from the Carnot CALYM Institute network and Inserm Transfert, Inserm’s private subsidiary, representing the research teams. This 3-year collaboration will allow the funding of up to two projects per year.
This agreement defines the terms of the collaboration with respect to governance, funding, intellectual property, exploitation of results and eligibility of research projects. It provides a platform facilitating the alliance between AstraZeneca’s R&D, bringing new drug candidates from its technology platforms of excellence, and the world-renowned expertise of the academic teams of the CALYM’s network, dedicated to the pathophysiology of lymphomas.
According to Bertrand Nadel, Director of CALYM, "Successful therapeutic innovation today requires interfacing academic expertise with R&D practices and the drug development value chain and intensifying the dialogue between public and private players. AstraZeneca’s commitment to connecting the Discovery/Innovation/Transfer segments makes it a partner of choice for our Carnot CALYM Institute to meet this challenge".